All Episodes
pharmaphorum Podcast — 354 episodes
Ethical AI & trust-driven innovation: UCB’s Erik Janssen
Delivering prevention at scale, PA Consulting’s James Davis
Understanding Operation Trialblazer, with Dr Harpreet Singh
Prevent-Stop-Cure: Diagnostics & chronic liver disease, with Roche
Policy in Focus: What’s new with CMS drug price negotiation, with Alice Valder Curran
CAMP4 on a new class of ASO in gene under expression
BonelliErede on M&A in Europe: Andrea Carta Mantiglia
Purespring on nephrology & gene therapy in kidney disease
Parexel: Flawless execution, policy shifts & patient-centric design
Citius’ Leonard Mazur talks targeted immune therapy for CTCL
Radiopharma in 2026 & beyond, with ITM's Dr Andrew Cavey
Biosimilars & patient access independent of geographies or socioeconomics, with Rebecca Guntern
Towards a healthier world: Momentum in UK health system transformation, with Lee-Ann Farrell
Trustworthy and novel AI in clinical trial planning, with Kris Kaneta
The cardio-renal-metabolic space and obesity as a chronic disease, with Ramy Younes
On the power of T-cells, with Cedrik Britten
Why everyone should care about longevity, with Boyang Wang
A philosophical look at market turn in the Age of AI, with John Holodnak
Providing patient access to new therapies, with Dean Erhardt
Pushing through barriers to commercial launch success, with Amanjeet Singh Saluja
Every drug is a story, with Thomas Goetz
Looking to gene therapy for ocular diseases, with Lance Baldo
Creating what nature has not from AI and computational molecular biophysics with Kashif Sadiq
On collaboration, computational chemistry, and cutting-edge AI – with Olga Nissan
Making AI work where it matters, with Rob DiCicco
Treating genetic disease at scale with tRNA, with Michelle Werner
AI in clinical development & ‘white space’, with Andrew Mackinnon
Collaboration & personalisation in rare disease R&D, with AOP Health’s Melissa Fellner
Policy in Focus: Unpacking GLOBE, GUARD, and TrumpRx with Alice Valder Curran
On JPM2026 and healthcare investment today, with Jonah Comstock
On addressing drug waste and ensuring access, with Jeff Harper
From Buzzword to Strategy: Reverba Global Talks Omnichannel Engagement on the pharmaphorum Podcast
On quality data for quality learnings, with Lisa Sims
JPM2026: Broadening AI drug discovery to include the lab, with Yann Gaston-Mathe
On AI and equity in the cancer setting, with Mohit Manrao
JPM2026: AI diagnostics and translational research, with Andrew Beck
Shaping the future of immunodeficiency care, with Dr Jörg Schüttrumpf
Aligning with national efforts to modernise cancer diagnostics, with Andrew Newland
Rethinking prescription drug affordability, with Vinay Patel
An AI supercomputer and discovering next-gen brain disorder treatments, with Tarek Samad
On genomics, NGS, and doing much more good than bad, with Markus Vossman
Delivering the right behavioural ingredients for the moment, with Amy Bucher
AI for the planet, AI for life sciences – with Patrick Leung
On the future of AI in life sciences, with women at the helm
On AI and computational support of biochemistry, with Alan Roth
Harnessing the cell's own degradation machinery, with Benedict Cross
How blood tests can inform cancer treatment decisions, with Craig Eagle
The NHS, system burden, and a transformation prescription, with Ruth Chambers
On CB1s as an alternative to GLP-1s, with Punit Dhillon
Digital transformation as a third lever in the affordability debate, with Alfred Olivares
Towards a democratic era of medicine, with Simon Kohl
CDMOs: Their crucial role and how to select one, with Sigma Mostafa
On US drug shortages and compounding pharmacies, with Shawn Hodges
Delving into the physics of cancer, with Lew Bender
On inflammation, heart health, and GLP-1 possibilities, with Sandeep Kulkarni
On digital twins in rare disease research, with Piet van der Graaf
The hot topics of digitisation, with Rob Verheul
Ten years of innovation at Frontiers Health – Live from Berlin with Jessica DaMassa
Working together to innovate on pragmatic clinical trials, with Rob DiCicco
Policy in Focus: Trump’s MFN deals, FDA vouchers, and the government shutdown
Biotech’s biggest challenge isn’t scientific, but political – with James Roosevelt Jr
On targeted radiotherapeutics, with Marc Hedrick
Towards one, cohesive AI workflow: In conversation with Ilya Burkov
Collaborating on a connected platform journey, with Alexander Alex and Florian Schnappauf
ESMO25: Patient-centric oncological futures with Boehringer Ingelheim
Smoothing a contract pathway through uncertainty: In conversation with Neal Masia
FH25: On the future of health, with Frontiers Health Chairman Roberto Ascione
Allosteric small molecule therapies in PD, with Gene Mack
FH25: Jessica DaMassa on hosting, hype, and health innovation
Improving ROI on AI investments and data quality, with Dr Jay Anders
The importance of being disruption ready, with Brandon Pence
FH25: Commercialising Health Tech and Deeptech, with Pilar Fernández Hermida
Agentic AI, culture shifts, and commercialisation today: Anthony Cilento post-Axtria Ignite 2025
FH25: On patient access and equity, with Roberta Sarno
FH25: On healthcare innovation with Gary Monk
FH25: The art of connection at Frontiers Health with Aline Noizet
Policy in Focus: Trump’s Most Favoured Nations drug pricing scheme – with Alice Valder Curran
FH25: Exploring the intersection of patients, HCPs, and technology with Denise Silber
Doing good in people’s lives: Amy Burroughs discusses CML
FH25: Individual centric investing with Steve Seuntjens
Pharma and health advertising: Brian Coane on the necessity of humour
The glimmer of opportunity behind the storm: Ali Pashazadeh talks biotech investment
FH25: The intersection of tech, science & design with Unity Stoakes
Changing the drug development treatment paradigm: Hilary Eaton on AI and LLMs
Increasing trial efficiency: Adityo Prakash talks small datasets, real-world scenarios, and organoids
FH25: Ten years at the forefront of health innovation, with Kristin Milburn
MAPs, EAPs, and patient access: Suzanne Aitken on the challenges for pharma
Weighing in on GLP-1 drugs
The TechBio way: Brendan Frey talks genomics, AI, and RNA
Advancing the frontier of cancer diagnostics: Post-ASCO with Eric Matthews
Compliance baked into the design core: On AI in life sciences with Florian Schnappauf
Putting patients and their families first: Dr Corina Dutcus, post-ASCO 2025
Enhancing anti-tumour activity: A post-ASCO conversation with Dan Schmitt
Redefining the Future of Melanoma Treatment: Scancell's Bold Step Forward
Why Datavant bought Aetion, and what comes next, with Arnaub Chatterjee
Post-ASCO 25: Pamela Tenaerts on CGTs and digital-first long-term follow-up
Immune mediation, B-cell depletion, and female leadership – with Aoife Brennan
Ben Sidders on integrating causality in AI for R&D success
On nuclear medicine and oncology, SHINE technologies
Unicorns, AI, and the future of health: Highlights from HLTH Europe 2025
On patient-centric treatment decisions and the value of quantitative methodologies, in conversation with Marc Buyse
Maximising value by uniting the digital backbone: On a new Novo Nordisk and Veeva partnership
The changing landscape of drug clinical assessment: Tommy Bramley on the JCA
Precision, speed, impact: Evolving mass spectrometry for medical science
IMUNON at ASCO 2025: Changing the micro-tumour environment in advanced ovarian cancer
Treating primary bone cancer: The potential of listeria-based bioengineered bacterial immunotherapy
Servier’s ASCO 2025 Data: Advancing IDH-Mutated Cancer Treatment with Tibsovo & Voranigo
Where innovation meets collaboration: Live from Manchester’s City labs 4.0
Live from ASCO 2025: Boehringer Ingelheim on unmet needs and oncology innovation
Bringing patients to research centres: Using AI to bring efficiencies forward
The need for a science-first mindset: The vaccine landscape today
EAPs: Market access outside of the US and Western Europe
The value of a partner, globally and locally
The ins and outs of HEOR – A lever for global health
Unpacking Trumps executive order on drug pricing with Alice Valder Curran
AI in drug development: The real hurdle is implementation
Patients as active consumers of care: AI-driven personalisation in pharma marketing
Driving the drug discovery pipeline: The value of organ-on-a-chip MPS
Intelligent regulatory compliance and improved patient outcomes
Prevention for a healthier, more productive society
Safeguarding the pharmaceutical supply chain
For the continuum of mental health we need a whole system, holistic 'healthspan'
IRA updates and making sense of the chaos in Washington, with Alice Valder Curran
GenAI and the revolution of drug development
Patient-focused manufacturing models for personalised therapies
On specialty pharmacies and prior authorisations
Paediatric rare diseases: Children are not small adults
Defining, building, and implementing in the next wave of biopharma R&D
Insights from JP Morgan Healthcare 2025: Key trends shaping the pharma industry
‘Show me the molecule’ – On synthetic biology and cutting through AI hype
Simulated clinical trial populations and AI scalability
Rare disease and the women's health gap
From science fiction to reality: AI in drug development
Precision medicine, NGS, and the quantum leap in biomarkers
Seeking effective, safe treatment for all with precision dosing
Seeking effective, safe treatment for all with precision dosing
CAR-T therapies: Faster, better, cheaper
Looking to history to prepare for America’s uncertain future
Next gen wearables: Transforming remote patient care
From neurosurgery to focused ultrasound: Not if, but when
A journey from personal to public: Digital health passports today
Access to genomic surveillance: Open science and public health
Advancing Precision Care For All
Investment outlook: Key takeaways from LSX USA
Oncology today: Eversana and pharmaphorum at ESMO 2024
Medicare drug pricing negotiations: What comes next?
The Life Sciences Generative AI Council and a sustainable technological future
Can self-navigating ADCs replace chemotherapy in the future?
Structuring the unstructured: Deterministic AI and white box data cleanliness
People need to know how to use AI now
Chronic cough and the patient voice
Approaching the regulatory world with passion: CERs and EU MDR processes
Patient engagement throughout the product lifecycle
The empowerment of data and predictive outcome models
The burden of diabetic vision loss in the West
Tips for on-time tech transfers that stay below budget
Clinical trial trends and the rise of site networks
A spectrum of obesity requires precision
The power and potential of regenerative medicine
Leveraging data and AI for clinical trial success
The future of fertility and the vaginal microbiome
Sustainable innovation for patients, people, and planet
The new frontier of microbiome-directed human health
Global medicines and the future outlook
Purity, potency, and safety – affordably – in stem cell therapy
The art of software
Move over CAR-T: The potential of NK cells in cell therapy
Working for a mature form of genomic medicines
Challenges and opportunities in synthetic clinical trials
The commercialisation of quantum science in pharma
Conference report: Reuters Pharma Europe
In vitro gametogenesis: the science has to be right, and it has to be safe
Proving ROI for digital endpoints
Clinical trials: their design, location, and, potentially, their simulation
Pace, acceleration, and precision are the name of the game
Technology working as the puzzle piece to bring better outcomes to patients
Is precision psychiatry possible?
Encouraging early engagement to revitalise Europe’s pharmaceutical landscape
Predictions for AI in mental health in the coming year
Fixing clinical trial data management
Harnessing the velocity of biopharmaceutical advances
Conference report: Reuters Pharma USA
The future of AI: Machine learning working together with scientific expertise
Understanding the politics of drug pricing in the United States
Female leadership and lessening disease burden
The unique clinical trial challenges faced by digital therapeutics
The unmentionables: Challenging inequalities in women’s health
The next chapter for AI protein structure prediction
Avoiding the data swamp: The transformative power of AI
How natural language processing can make a difference in pharma
Transitioning from traditional surgical methods to the innovative use of stem cells.
The 2024 biopharma M&A landscape: An overview
Accelerating the process, transforming therapies and advancing precision medicine
Applying genetics to chemistry to find new small molecules
Opening the digital front door to advanced healthcare
Pharmaceutical research in space
Precision medicine in mental health - one size really doesn’t fit all
Where are the pharma voices in US politics?
A clearer harmony and attractiveness for EU Clinical Trials Regulation
Making connections and getting noticed as a biotech start-up
Getting down to the nitty gritty of actively creating healthier societies
How manufacturing keeps pace with innovation in cell and gene therapy
Fixing the inequity of drug access outside of the US
Key themes from JP Morgan
Prediction is very difficult, especially if it’s about the future
Promoting value-added medicines and renovating old medicines smartly
Digitisation of drug R&D: Avoiding new for novelty’s sake
The problems of animal research for human medicine and the alternatives
The race to develop innovative products and supply chain solutions
The smart-design evolution of the laboratory space
Investing in the gleams of positivity and hope for life sciences innovation
Looking to the future of UK medical device exports
Exploring the reasons behind increasing burdens on clinical research sites
An investor’s perspective on bio and tech
Why digital therapeutics (DTx) are effective and safe, but not being prescribed
AI drug discovery: Where we are and where we’re going
Retaining the human element in healthcare services whilst embracing the potential of robotics
Bringing women’s health up to speed for 21st Century human healthcare
Creating a future where the healthcare ecosystem works for everyone
Key themes from Frontiers Health 2023, with the pharmaphorum team
Reducing the stigma attached to psychedelics
How birth tissue donations are fuelling the cell therapy revolution
Immunometabolism: Providing a new era of targeted medicine
Retaining the human element of AI within pharma and healthcare
Resilience, empathy, and gratitude. A personal battle with breast cancer.
The ‘elegant science’ in achieving the promise of ADCs
Understanding the importance of the whole person in clinical research
Why medical weight loss is more complicated than GLP-1s
Creating behavioural change through incremental, small steps
How AI can bolster each step of the clinical trial journey
Focussing on finding value in health sciences marketing
How big pharma cares for its own
Embracing the challenges and opportunities of digital health
How AI and omnichannel are transforming pharma marketing
Digital therapeutics at a turning point: What we heard at DtX East
Understanding and addressing care disparities in rare cancers
Turning drug development on its head
GLP-1 Weight loss drugs: An overview and update
Biopharma’s rapid transition to omnichannel marketing
Partnering for holistic care
Mapping the landscape of clinical trial regulation
Preparing for the tsunami of healthcare data approaching
Alzheimer’s drugs: An overview and update
Suffering beyond physical effects: inequalities and taboos in prostate cancer
Collaborative perseverance to bring change to medicine access
Botanicals in pharma: Potential and pitfalls
Clinical trial diversity: An update
Changing personnel dynamics in the pharma world
Retaining the human quality of healthcare in DTx
Focusing on predictability and execution in digital trials
Genetic testing update with 23andMe’s Noura Abul-Husn
Headlines and hot topics from ASCO and BIO
The precision element at the heart of digital transformation
AI in drug development: A reality check
Epiphany moments in an industry starved of insights
A closer look at gene therapy with PTC Therapeutics
WWD: Ready, Set, Food! CEO, Daniel Zakowski
The Hidden Burden of Stigmatised Health Conditions
Creating healthier futures - Reuters Pharma Barcelona 2023
Inside the new world of healthcare data
Restoring sensitivity to targeted therapies
Insulin costs & pharma manufacturing
What the low impact of Humira biosimilars teaches us about drug prices
Transforming healthcare: Nils Bottler and Paul Tunnah
Challenges and opportunities with plasma-derived therapies
CinCor Pharma: A small pharma’s journey to acquisition
AI trends in 2023
Accelerating digital healthcare, with VITA
Investing in healthcare’s future, with Paul Tunnah and Elia Stupka
Solving problems in pathology data, with Nathan Buchbinder
How Moderna kept diversity in mind amid vaccine development
Key themes from JP Morgan, with Paul Tunnah
Cancer control in a time of crisis
The scattered seeds of the beginnings of change
A few of the 2022’s biggest pharma trends
Exploring the importance we play in our own health maintenance
Focusing on the evolution of biotechnology and R&D
Innovations in Real-World Evidence (live from PharmStars)
Continuing to keep COVID-19 at bay
Can VR technology make physical therapy fun
Exploring a united vision for British pharma at Anthropy
What we heard and saw at HLTH22, with Matthew Holt
Disrupting the standard of healthcare for Bangladesh
How immersive audio can be a therapeutic tool
A new hope in cachexia and an outsider’s view on pharma
Why is digital health so challenging for big tech?
Live from Frontiers Health 2022 - the pharmaphorum podcast
Live from Reuters Pharma 2022 - the pharmaphorum podcast
Building agile partner relationships at a vaccine-focused biotech
Understanding the tumour micro-environment – the pharmaphorum podcast
How a once-weekly insulin could disrupt diabetes management
How these parents of a child with a rare disease are making precision medicine work for them
AI-derived cancer vaccines
Challenges and opportunities in the off-patent sector
Building a digital therapeutic for paediatric behavioural health opioids
Gene silencing and mRNA: breakthroughs and barriers
Rethinking pharmaceutical pain management beyond opioids
Why diverse clinical trials matter
Where pharma stands on patient centricity, engagement, and trust
How pharma can spur innovation and promote health equity in mental health
Innovative solutions to the drug pricing crisis: the pharmaphorum podcast
Big data and how it can change the game in pharma: the pharmaphorum podcast
The year ahead in digital health and life sciences: the pharmaphorum podcast
The evolution of clinical trials: the pharmaphorum podcast
Patient engagement processes: the pharmaphorum podcast
Real-world evidence and qualitative research: the ELICIT podcast
Merck on trends in oncology: the pharmaphorum podcast
Sandoz’s Pierre Bourdage on biosimilars: the pharmaphorum podcast
Patient engagement strategies: the pharmaphorum podcast
BMS’ Catherine Owen on pharma commercialisation: the pharmaphorum podcast
Novartis’ Amit Nastik on COVID’s supply chain impact: the pharmaphorum podcast
Virtual engagement and collaborations: the pharmaphorum podcast
Biotech Insight podcast: Overcoming planning challenges in oncology
Vertex senior country manager Nicola Massey: the pharmaphorum podcast
Regenerative medicine and COVID: the pharmaphorum podcast
Pharmacy and clinical research: the pharmaphorum podcast
Pharma’s post-COVID prospects: the pharmaphorum podcast
Galapagos UK’s Michael Smyth on COVID and RNA-based tech: the pharmaphorum podcast
Big data and cell therapy development: the pharmaphorum podcast
GSK on COVID and vaccine development: the pharmaphorum podcast
The meaning of digital innovation: the pharmaphorum podcast
New ways to treat COVID: the pharmaphorum podcast
The Alderley Park Discovery Podcast: The journey to accessing science funding and investment
Roche on COVID healthcare and testing: the pharmaphorum podcast
Richard Francis discusses his new role as Purespring’s CEO: pharmaphorum podcast
AstraZeneca’s Rebekah Martin on diversity and inclusion: the pharmaphorum podcast
The Alderley Park Discovery Podcast: Life science skills, staffing and support
J&J and medical device innovation: the pharmaphorum podcast
Biotech trends in COVID era: the pharmaphorum podcast
GSK and eosinophil research: the pharmaphorum podcast
Gitte Aabo on telemedicine and her time at LEO Pharma: the pharmaphorum podcast
The Alderley Park Discovery Podcast: COVID testing and the Lighthouse Lab
Alnylam, gene-silencing and biotech in 2020: the pharmaphorum podcast
Novartis, company culture and COVID-19: the pharmaphorum podcast
Amgen and science education: the pharmaphorum podcast
UK pharma leadership and COVID-19: the pharmaphorum podcast
Eisai and Alexa skills in epilepsy: the pharmaphorum podcast
Digital health and interoperability: the pharmaphorum podcast
Roche, big data and patient outcomes: the pharmaphorum podcast
Pfizer and the UK cancer landscape: the pharmaphorum podcast
Life sciences leadership: the pharmaphorum podcast
AstraZeneca and lung cancer: the pharmaphorum podcast
Lung cancer’s patient information gap: the pharmaphorum podcast
The state of UK drug discovery: the pharmaphorum podcast
Addressing global health challenges: the pharmaphorum podcast
Gene therapy and market access: the pharmaphorum podcast
AMR research and Matoke Pharma: the pharmaphorum podcast
GSK and digital disruption: the pharmaphorum podcast
Ipsen on neurotoxin research: the pharmaphorum podcast
Successful medical marketing teams: the pharmaphorum podcast
Biotech strategy and nanomedicine: the pharmaphorum podcast
Commercialising orphan drugs: the pharmaphorum podcast
The future biosimilar landscape: the pharmaphorum podcast
Nimble consumer healthcare innovation: the pharmaphorum podcast